


The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA
Myocardial Inflammation Elevated in Active RA, Eases with DMARD Therapy

Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies

3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA

Rheumatology Drug Updates on Brentuximab Vedotin, Tofacitinib Citrate

High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
Socioeconomic Factors Contribute to Inconsistent Use of DMARDs Among Patients with RA

Why Do We Wait to Help Patients?
